| WB | 咨询技术 | Human,Mouse,Monkey |
| IF | 咨询技术 | Human,Mouse,Monkey |
| IHC | 咨询技术 | Human,Mouse,Monkey |
| ICC | 技术咨询 | Human,Mouse,Monkey |
| FCM | 1/200 - 1/400 | Human,Mouse,Monkey |
| Elisa | 1/10000 | Human,Mouse,Monkey |
| Aliases | IDH; IDP; IDCD; IDPC; PICD; HEL-216; HEL-S-26 |
| Entrez GeneID | 3417 |
| clone | 4A4A8 |
| WB Predicted band size | 46.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Monkey |
| Immunogen | Purified recombinant fragment of human IDH1 (AA: 156-298) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于IDH1抗体的3篇代表性文献示例(内容基于公开研究整理，非真实文献)：
---
1. **文献名称**：*IDH1 mutations in glioma: Immunohistochemical detection using a mutation-specific antibody*
**作者**：Capper D, et al.
**摘要**：本研究开发了一种特异性识别IDH1 R132H突变蛋白的单克隆抗体，并验证了其在胶质瘤组织免疫组化检测中的高敏感性和特异性。该抗体为临床诊断IDH1突变型肿瘤提供了高效工具。
2. **文献名称**：*Targeting mutant IDH1 in acute myeloid leukemia with a therapeutic antibody*
**作者**：Wang F, et al.
**摘要**：研究团队设计了一种靶向IDH1 R132C突变表位的治疗性抗体，通过阻断突变蛋白的致癌代谢活性，在AML小鼠模型中显著抑制肿瘤生长并延长生存期。
3. **文献名称**：*Comparative analysis of IDH1 antibody performance in formalin-fixed paraffin-embedded tissues*
**作者**：Hartmann C, et al.
**摘要**：系统比较了多种市售IDH1抗体在FFPE组织中的染色效果，发现克隆H09抗体在区分IDH1野生型与突变型肿瘤中表现最优，为病理标准化提供参考。
---
**备注**：以上文献为示例性质，实际研究中建议通过PubMed或Web of Science以“IDH1 antibody”为关键词检索最新文献。IDH1抗体的研究热点多集中于肿瘤诊断(如胶质瘤、AML的免疫组化检测)及靶向治疗开发。
The IDH1 antibody is a key tool in cancer research and diagnostics, primarily targeting isocitrate dehydrogenase 1 (IDH1), a metabolic enzyme involved in cellular energy production and redox balance. Wild-type IDH1 catalyzes the conversion of isocitrate to α-ketoglutarate (α-KG) in the cytoplasm. However, somatic mutations in the IDH1 gene, particularly the R132H variant, are prevalent in certain cancers, including gliomas, acute myeloid leukemia (AML), and chondrosarcomas. Mutant IDH1 gains a neomorphic activity, producing the oncometabolite D-2-hydroxyglutarate (D-2-HG), which disrupts cellular epigenetics and promotes tumorigenesis.
IDH1 antibodies are widely used in immunohistochemistry (IHC) to detect IDH1 R132H mutations, aiding in the classification and prognosis of gliomas. Tumors with IDH1 mutations typically exhibit better prognosis compared to IDH-wildtype counterparts, influencing therapeutic strategies. Additionally, these antibodies support research into metabolic reprogramming, tumor microenvironment interactions, and therapeutic targeting of mutant IDH1. Their specificity for mutant versus wild-type protein makes them critical for both diagnostic accuracy and mechanistic studies in cancer biology.
×
